Douglas Day, MD
Ophthalmology · Atlanta, GANPI 1447288246
Payments from drug & device makers
Across 531 payments — averaging $2031.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$713K
- Padagis US LLC$153K
- Glaukos Corporation$67K
- Kala Pharmaceuticals, Inc.$38K
- Alcon Research LLC$32K
- Aerie Pharmaceuticals, Inc.$30K
- plus $46K from 19 others
Across 8 payments — averaging $232.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$9,80619%
- Speaking & faculty fees$19,45038%
- Travel & lodging$13,84327%
- Food & beverage$8,51216%
- Gifts$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 384 | $712,800 |
| Padagis US LLC | 5 | $153,100 |
| Glaukos Corporation | 39 | $67,342 |
| Kala Pharmaceuticals, Inc. | 16 | $37,832 |
| Alcon Research LLC | 4 | $32,148 |
| Aerie Pharmaceuticals, Inc. | 7 | $30,128 |
| Amneal Pharmaceuticals LLC | 3 | $28,228 |
| Ocular Therapeutix, Inc. | 2 | $7,565 |
| Osmotica Pharmaceutical Corp. | 3 | $7,181 |
| Ivantis, Inc | 5 | $589 |
| Alcon | 13 | $367 |
| Sight Sciences, Inc. | 3 | $365 |
| Eyepoint US, Inc. | 2 | $250 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $187 |
| Novartis | 18 | $171 |
| Rxsight Inc | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Sun Pharmaceutical Industries Inc. | 4 | $91 |
| Bausch & Lomb Americas Inc. | 3 | $60 |
| Thea Pharma Inc. | 2 | $49 |
| Akorn Operating Company LLC | 2 | $44 |
| Akorn, Inc. | 1 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Shire North American Group Inc | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$17,391
- XEN$5,099
- LUMIGAN$3,179
- COMBIGAN$3,179
- Hydrus$479
- DEXYCU$250
- OMNI$197
- iDoseTR$162
- iStent inject W$149
- XEN GLAUCOMA TREATMENT SYSTEM$148
- OMNI(R) SURGICAL SYSTEM (US)$147
- Rocklatan$125
- Rhopressa$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Tecnis IOL$123
- iStent Trabecular Micro-Bypass System Model iS3$102
How this compares
$1,078,865 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 850 | $508,964 |
| CombiganBrimonidine Tartrate/Timolol | 381 | $168,635 |
| RocklatanNetarsudil Mesylat/Latanoprost | 188 | $107,409 |
| RhopressaNetarsudil Mesylate | 154 | $88,712 |
| Alphagan PBrimonidine Tartrate | 176 | $83,907 |
| VyzultaLatanoprostene Bunod | 141 | $78,248 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 301 | $63,790 |
| RestasisCyclosporine | 63 | $62,705 |
| Travoprost | 246 | $45,015 |
| Brimonidine Tartrate | 1,167 | $43,821 |
| Betaxolol Hcl | 408 | $41,356 |
| Latanoprost | 2,993 | $41,201 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 115 | $32,814 |
| Brinzolamide | 96 | $21,614 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 924 | $18,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $712,800 | $824,2111,470 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $30,128 | $196,121342 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $60 | $78,248141 claims |
| AlconSimbrinza | $367 | $32,814115 claims |
| NovartisTravatan Z | $171 | $13,59025 claims |
| Akorn, Inc.Zioptan | $42 | $9,37930 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $187 | $8,50844 claims |
| Thea Pharma Inc.Iyuzeh | $49 | $6,20215 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $37,832 | $5,28318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Atul SharmaAtlanta$193K
- Chris BergstromAtlanta$139K
- Anastasios CostaridesAtlanta$137K
- Evan SchoenbergAtlanta$130K
- Jiong YanAtlanta$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.